Company Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders.
Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials.
In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders.
The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Kevin Koch |
Contact Details
Address: 1715 38th Street Boulder, Colorado 80301 United States | |
| Phone | 720-262-7002 |
| Website | edgewisetx.com |
Stock Details
| Ticker Symbol | EWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001710072 |
| CUSIP Number | 28036F105 |
| ISIN Number | US28036F1057 |
| Employer ID | 82-1725586 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kevin Koch Ph.D. | President, Chief Executive Officer and Director |
| Dr. Behrad Derakhshan Ph.D. | Chief Operating Officer |
| Dr. Joanne M. Donovan M.D., Ph.D. | Chief Medical Officer |
| Dr. Alan J. Russell Ph.D. | Co-Founder, Chief Scientific Officer and Director |
| R. Michael Carruthers | Chief Financial Officer |
| John R. Moore J.D. | General Counsel |
| Dr. Robert Blaustein M.D., Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | 10-Q | Quarterly Report |
| May 8, 2025 | 8-K | Current Report |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2025 | 424B5 | Filing |
| Apr 2, 2025 | 8-K | Current Report |
| Apr 2, 2025 | 8-K | Current Report |
| Mar 3, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 3, 2025 | 10-K | Annual Report |
| Mar 3, 2025 | 8-K | Current Report |